What is the difference between Amycretin and Retatrutide?

Amycretin is classified as: Unimolecular GLP-1 and amylin receptor co-agonist. Retatrutide is classified as: Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide). Amycretin is investigational and is not an approved medicine. Retatrutide is investigational and is not an approved medicine.

Is Amycretin or Retatrutide approved?

Amycretin is investigational and is not an approved medicine. Retatrutide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Amycretin and Retatrutide?

Peptide Science Daily tracks 21 registered clinical trials for Amycretin (evidence grade C) and 34 for Retatrutide (evidence grade B).

Compound comparison

Amycretin vs Retatrutide

This page sets Amycretin and Retatrutide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Amycretin
Unimolecular GLP-1 and amylin receptor co-agonist
Retatrutide
Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)
Mechanism: Amycretin
In plain terms, amycretin is one molecule that acts on two appetite-regulating targets at once: the GLP-1 receptor, the target of drugs such as semaglutide, and the amylin receptor.
Retatrutide
In plain terms, retatrutide mimics several natural gut and pancreatic hormones at once to reduce appetite and food intake while affecting how the body handles glucose and energy.
United States (FDA): Amycretin
Not approved. Investigational only; in early-to-mid phase clinical development for obesity and not authorized for any indication.
Retatrutide
Investigational; not approved. Phase 3 TRIUMPH program ongoing, with a first positive topline readout (TRIUMPH-4) reported in December 2025.
European Union (EMA): Amycretin
Not authorized. Investigational; no EU marketing authorisation.
Retatrutide
Not authorized; investigational, no marketing authorization.
Australia (TGA): Amycretin
Not registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia.
Retatrutide
Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
WADA: Amycretin
Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide).
Retatrutide
Not listed on the WADA Prohibited List. As an investigational incretin-class agent it is not a banned substance; the closely related approved GLP-1 agonists are on WADA's monitoring program rather than prohibited.
Evidence grade: Amycretin
C
Retatrutide
B
Tracked clinical trials: Amycretin
21
Retatrutide
34
Full profile: Amycretin
Amycretin profile
Retatrutide
Retatrutide profile

Comparison of Amycretin and Retatrutide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Amycretin	Retatrutide
Class	Unimolecular GLP-1 and amylin receptor co-agonist	Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)
Mechanism	In plain terms, amycretin is one molecule that acts on two appetite-regulating targets at once: the GLP-1 receptor, the target of drugs such as semaglutide, and the amylin receptor.	In plain terms, retatrutide mimics several natural gut and pancreatic hormones at once to reduce appetite and food intake while affecting how the body handles glucose and energy.
United States (FDA)	Not approved. Investigational only; in early-to-mid phase clinical development for obesity and not authorized for any indication.	Investigational; not approved. Phase 3 TRIUMPH program ongoing, with a first positive topline readout (TRIUMPH-4) reported in December 2025.
European Union (EMA)	Not authorized. Investigational; no EU marketing authorisation.	Not authorized; investigational, no marketing authorization.
Australia (TGA)	Not registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia.	Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
WADA	Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide).	Not listed on the WADA Prohibited List. As an investigational incretin-class agent it is not a banned substance; the closely related approved GLP-1 agonists are on WADA's monitoring program rather than prohibited.
Evidence grade	C	B
Tracked clinical trials	21	34
Full profile	Amycretin profile	Retatrutide profile

Common questions

What is the difference between Amycretin and Retatrutide?: Amycretin is classified as: Unimolecular GLP-1 and amylin receptor co-agonist. Retatrutide is classified as: Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide). Amycretin is investigational and is not an approved medicine. Retatrutide is investigational and is not an approved medicine.
Is Amycretin or Retatrutide approved?: Amycretin is investigational and is not an approved medicine. Retatrutide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Amycretin and Retatrutide?: Peptide Science Daily tracks 21 registered clinical trials for Amycretin (evidence grade C) and 34 for Retatrutide (evidence grade B).